Development of novel treatments of neurodegeneration diseases
In the frontline of fighting neurodegeneration, the toughest CNS targets in drug development, a new alliance has formed by Roche and reMYND, a Belgian biotech compnay. The companies announced that they have entered into an agreement to develop novel treatments that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting ?-synuclein and tau toxicity.
The agreement involved novel compounds from ReMYND’s compounds which are disease modifying therapies that inhibit ?-synuclein neurotoxicity in Parkinson’s disease and tau neurotoxicity in Alzheimer’s disease, two of the candidate compounds are in the preclinical development. ReMYND could get paid for more than $637 million in milestones if the new treatments can make their way to the marketplace.
While Roche will be working on lead-optimisation and other pre-clinical development, ReMYND would continue with pharmacology studies and further elucidate the underlying molecular mechanisms. Roche will be responsible for all clinical development and worldwide commercialisation.
Focused on neurodegeneration diseases, ReMYND has six programs in its pipeline in various stages of preclinical development for Parkinson’s and Alzheimer’s.
“Our most advanced compound in Parkinson’s disease has demonstrated full inhibition of disease progression in pre-clinical models and could be the first treatment in clinical development for Parkinson’s disease targeting ?-synuclein-induced toxicity,” says Gerard Griffioen, CSO of reMYND.
Recently, Eli Lilly has to stop its late-stage Alzheimer’s program after they found that it could have worsen the conditions of the patients taking it. According to the latest statistics from the WHO, there are currently around 35 million people diagnosed with Alzheimer’s disease.
Although it is a tough task to find effective therapies against neurodegeneration, including Alzheimer’s disease that is growing rapidly as the world’s population ages, scientists from academia and industry are determined to find new effective targets to cure these neurodegeneration diseases.